文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

基于有限证据获FDA初始批准药物的上市后研究:系统综述

Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review.
PubMed 文献 · BMJ · 2017-05-03

该系统综述评估了2005至2012年间FDA基于单个关键试验、替代终点关键试验或两者批准的新药上市后前瞻性对照临床研究。共纳入117种药物对应123个适应症,中位随访5.5年后识别758项已发表对照研究,但35.0%的适应症无上市后研究,且仅少数研究以临床结局证实疗效。

要点

  • 2005至2012年FDA基于有限证据批准117种新药对应123个适应症。
  • 中位5.5年后识别758项上市后对照研究,73.1%为替代终点适应症研究。
  • 35.0%的适应症无上市后研究,仅少数以临床结局证实疗效。

核心结论

  • 基于有限证据首次获FDA批准的新药,其上市后临床证据的数量和质量差异很大,且很少有上市后对照研究使用临床结局证实原FDA批准适应症的疗效。

研究设计与样本

  • 系统综述,检索Drugs@FDA数据库和PubMed,纳入2005至2012年间FDA基于单个关键试验、使用疾病替代标志物作为主要终点的关键试验或两者批准的所有新药,以及批准后发表的所有前瞻性对照临床研究。

主要发现

  • 2005至2012年FDA基于单个关键试验、替代标志物关键试验或两者批准了117种新药对应123个适应症。
  • 批准后中位5.5年(四分位间距3.4-8.2)内识别758项已发表对照研究,其中554项(73.1%)为基于替代标志物批准的适应症研究。
  • 使用活性对照的研究比例:单个关键试验批准适应症为67/77(87.0%),替代标志物试验批准为365/554(65.9%),单个替代试验批准为100/127(78.7%)。
  • 以疗效替代标志物为主要终点的研究比例:单个关键试验批准为51/77(66.2%),替代标志物试验批准为512/554(92.4%),单个替代试验批准为110/127(86.6%)。
  • 123个批准适应症中43个(35.0%)未识别到任何上市后研究;上市后研究中位总数分别为1(0-2)、3(1-8)和1(0-2),中位累计入组患者数分别为90(0-509)、533(122-3633)和38(0-666)。

关键数值与推荐

  • 批准后发表至少一项使用临床结局为主要终点、随机对照双盲研究且显示优效的适应症比例:单个关键试验批准为18.2%(6/33),替代标志物试验批准为2.0%(1/49),单个替代试验批准为4.9%(2/41)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective To characterize the prospective controlled clinical studies for all novel drugs that were initially approved by the Food and Drug Administration on the basis of limited evidence.Design Systematic review.Data sources Drugs@FDA database and PubMed.Study inclusion All prospective controlled clinical studies published after approval for all novel drugs initially approved by the FDA between 2005 and 2012 on the basis of a single pivotal trial, pivotal trials that used surrogate markers of disease as primary endpoints, or both. Results Between 2005 and 2012 the FDA approved 117 novel drugs for 123 indications on the basis of a single pivotal trial, pivotal trials that used surrogate markers of disease, or both (single surrogate trials). We identified 758 published controlled studies over a median of 5.5 years (interquartile range 3.4-8.2) after approval, most of which (554 of 758; 73.1%) were studies for indications approved on the basis of surrogate markers of disease. Most postapproval studies used active comparators-67 of 77 (87.0%) indications approved on the basis of single pivotal trials, 365 of 554 (65.9%) approvals based on surrogate marker trials, and 100 of 127 (78.7%) approvals based on single surrogate trials-and examined surrogate markers of efficacy as primary endpoints-51 of 77 (66.2%), 512 of 554 (92.4%), and 110 of 127 (86.6%), respectively. Overall, no postapproval studies were identified for 43 of the 123 (35.0%) approved indications. The median total number of postapproval studies identified was 1 (interquartile range 0-2) for indications approved on the basis of a single pivotal trial, 3 (1-8) for indications approved on the basis of pivotal trials that used surrogate markers of disease as primary endpoints, and 1 (0-2) for single surrogate trial approvals, and the median aggregate number of patients enrolled in postapproval studies was 90 (0-509), 533 (122-3633), and 38 (0-666), respectively. The proportion of approved indications with one or more randomized, controlled, double blind study using a clinical outcome for the primary endpoint that was published after approval and showed superior efficacy was 18.2% (6 of 33), 2.0% (1 of 49), and 4.9% (2 of 41), respectively.Conclusions The quantity and quality of postapproval clinical evidence varied substantially for novel drugs first approved by the FDA on the basis of limited evidence, with few controlled studies published after approval that confirmed efficacy using clinical outcomes for the original FDA approved indication.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Pease AM, Krumholz HM, Downing NS, et al. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ. 2017. PMID: 28468750. doi:10.1136/bmj.j1680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。